Gland FDA Friday, July 31, 2026 +0.25 Positive

FDA Approves ATROPINE — Gland Pharma Limited

Gland Pharma Limited has received FDA approval for its Atropine Sulfate ophthalmic product, issuing new competition for the branded segment. Patients may soon benefit from a more favorable pricing environment as the availability of this generic alternative likely drives market share shifts.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed